stoxline Quote Chart Rank Option Currency Glossary
  
Cingulate Inc. (CING)
4.96  0.2 (4.2%)    06-26 16:00
Open: 4.72
High: 4.99
Volume: 329,398
  
Pre. Close: 4.76
Low: 4.67
Market Cap: 28(M)
Technical analysis
2026-06-26 4:43:08 PM
Short term     
Mid term     
Targets 6-month :  6.19 1-year :  7.23
Resists First :  5.3 Second :  6.19
Pivot price 4.84
Supports First :  3.97 Second :  3.16
MAs MA(5) :  4.86 MA(20) :  4.7
MA(100) :  5.81 MA(250) :  4.87
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  57.4 D(3) :  63.4
RSI RSI(14): 52.5
52-week High :  11.89 Low :  3.16
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CING ] has closed below upper band by 33.2%. Bollinger Bands are 70.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5 - 5.03 5.03 - 5.06
Low: 4.59 - 4.63 4.63 - 4.67
Close: 4.89 - 4.96 4.96 - 5.02
Company Description

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.

Headline News

Fri, 26 Jun 2026
Cingulate, Inc. Actuals & Estimates (NASDAQ:CING) - TradingView

Fri, 26 Jun 2026
CING Forecast — Price Target — Prediction for 2027 - TradingView

Thu, 04 Jun 2026
FDA focuses on manufacturing for Cingulate CTx-1301, not safety - Stock Titan

Thu, 04 Jun 2026
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 - TMX Newsfile

Tue, 02 Jun 2026
Cingulate ADHD drug faces FDA data request, no safety concerns cited - Stock Titan

Tue, 02 Jun 2026
Cingulate Receives Complete Response Letter from FDA for CTx-1301 - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 13 (M)
Shares Float 13 (M)
Held by Insiders 30.5 (%)
Held by Institutions 8.8 (%)
Shares Short 1,960 (K)
Shares Short P.Month 1,500 (K)
Stock Financials
EPS -4.33
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.58
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -69.7 %
Return on Equity (ttm) -225.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -0.73
Sales Per Share 0
EBITDA (p.s.) -1.76
Qtrly Earnings Growth 0 %
Operating Cash Flow -20 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -1.15
PEG Ratio 0
Price to Book value 3.13
Price to Sales 0
Price to Cash Flow -3.42
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android